Multimodality imaging in the detection and management of coronary and peripheral arterial disease in patients with cancer receiving cardiotoxic antineoplastic treatments. A clinical consensus statement of the ESC Council of Cardio-Oncology and the European Association of Cardiovascular Imaging (EACVI) of the ESC

Early detection of cancer and advances in treatment have significantly improved the survival rate of patients with cancer. Both cancer and its treatment can accelerate the onset of cardiovascular disease, adversely affecting prognosis of patients with cancer and survivors. Coronary artery disease (CAD) and peripheral artery disease (PAD) are common complications in patients with cancer. Cardiovascular imaging plays a central role in baseline risk assessment, detection, and treatment planning. The indications for the use of various imaging modalities are similar as in the general population. However, due to unique pathophysiological characteristics and clinical presentations of this population, the use of cardiac imaging in these vulnerable patients often needs to be adapted to the clinical circumstances and individual patient characteristics. In this clinical consensus statement, the European Society of Cardiology (ESC) Council of Cardio-Oncology and the European Association of Cardiovascular Imaging of the ESC have reviewed and summarized the current evidence in this field to aid clinicians in the selection of appropriate imaging modalities for the diagnosis, monitoring, and treatment of CAD and PAD in patients with cancer.